NCT04782960

Brief Summary

This study aimed to assess the effectiveness of the Subconjunctival bupivacaine on postoperative pain in Strabismus surgery under general anaesthesia.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2021

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 16, 2021

Completed
16 days until next milestone

First Posted

Study publicly available on registry

March 4, 2021

Completed
28 days until next milestone

Study Start

First participant enrolled

April 1, 2021

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2021

Completed
Last Updated

March 4, 2021

Status Verified

March 1, 2021

Enrollment Period

1 month

First QC Date

February 16, 2021

Last Update Submit

March 2, 2021

Conditions

Keywords

Subconjunctival bupivacaine.Strabismus surgery.Postoperative analgesia.

Outcome Measures

Primary Outcomes (1)

  • Visual analog scale (VAS) pain score

    Range, 0\_10;0,no pain ;10,worst pain

    5 minutes after extubation

Secondary Outcomes (1)

  • Nausea and vomiting

    24 hours postoperatively

Other Outcomes (8)

  • Patient satisfaction

    24 hours postoperatively

  • Visual analog scale (VAS) pain score

    30 minutes after extubation

  • Visual analog scale (VAS) pain score

    60 minutes after extubation

  • +5 more other outcomes

Study Arms (2)

20 patients receive Subconjunctival bupivacaine of the end of the surgery

ACTIVE COMPARATOR

20 patients receive Subconjunctival bupivacaine in the end of operation and monitoring postoperative pain score

Drug: Iocal anaesthetic bupivacaine

20 patients receive Subconjunctival placebo in the end of operation

PLACEBO COMPARATOR

20 patients receive Subconjunctival placebo in the end of operation and monitoring postoperative pain score

Drug: Placebo

Interventions

Local anaesthetic Subconjunctival bupivacaine

Also known as: Group (p)
20 patients receive Subconjunctival bupivacaine of the end of the surgery

0.9 saline

Also known as: Group (s)
20 patients receive Subconjunctival placebo in the end of operation

Eligibility Criteria

Age14 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • All patients aged 14 \_30 years old with body mass index 18\_28kg/m.
  • American Anaesthesiologist Association physical states I,II.
  • singed informed consent to participate in the study and were scheduled for strabismus operations under general anaesthesia.

You may not qualify if:

  • were patients with chronic pain.
  • ocular hypertension.
  • inability to communicate.
  • history of hematological disease.
  • allergy to local anesthetic drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Population Groups

Intervention Hierarchy (Ancestors)

DemographyPopulation Characteristics

Study Officials

  • Mohammad A Hamed, MD

    Fayoum University Hospital

    STUDY DIRECTOR

Central Study Contacts

Abeer Sh Goda

CONTACT

Amr H Mahmoud, Msc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecture of Anesthesiology

Study Record Dates

First Submitted

February 16, 2021

First Posted

March 4, 2021

Study Start

April 1, 2021

Primary Completion

May 1, 2021

Study Completion

May 1, 2021

Last Updated

March 4, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share